Atlas Signs Definitive Agreement to Acquire a Controlling Interest in Three Pharmacies Expanding its Cannabis Network in Israel

• Atlas Global Brands signs definitive agreement to acquire control of three Pharmacies in Israel licensed to sell cannabis products
• The medical cannabis pharmacies are located in three new cities, expanding Atlas’ geographical coverage across the country of Israel
• Inclusive of the previously announced definitive agreements, upon closing of these transactions, Atlas will own a majority interest in nine pharmacies along with a trading house distribution centre in Israel
  
  

CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, May 24, 2023 (GLOBE NEWSWIRE) -- Atlas Global Brands Inc. (“Atlas Global”, “Atlas” or the “Company”) (CSE: ATL), a cannabis company with expertise across the value chain, announces that on May 23, 2023 it entered into a definitive agreement (“Proposed Transaction”) for the acquisition of 51% of the outstanding securities of three Israeli private limited liability companies operating medical cannabis pharmacies (the “Pharmacies”).

“The addition of these three pharmacies will further expand our geographical coverage with modern designed pharmacies, a patient focused education platform and dispensaries tailored to consistent product assortment,” said Bernie Yeung, CEO of Atlas Global. “We believe that this acquisition will be beneficial to both patients and our shareholders, while continuing to expand our geographical coverage in Israel.”

Terms of the Proposed Acquisitions

Under the Proposed Transaction, Atlas will acquire a 51% interest in the three Pharmacies for 1,925,300 common shares of Atlas Global (the “Consideration Shares”) and NIS 4,000,000 (the “Cash Consideration”), equivalent to approximately CAD $1,459,144 payable at closing. Up to an additional 288,795 shares may be issued at each of the six-, twelve-, and eighteen-month anniversaries of the closing date of the Proposed Transaction (the “Closing Date”) in the event the closing share price of the Atlas common shares for the 10 preceding trading days is less than $1 for total additional share consideration of up to 866,385 Atlas common shares.

The Consideration Shares will be subject to a lock-up period of 36 months during which 15% shall be released every six months, commencing on the six-month anniversary of the Closing, and 25% will be released on the 36-month anniversary.  

Approximately NIS 1.2M in existing shareholder loans, and any additional shareholder loans advanced by the Sellers until Closing, is expected to remain with the pharmacies, repayable from up to 25% of distributable profits from the pharmacies, cash flow permitting.